Effector CD4+ T-cell subsets in Takayasu arteritis-differences between the peripheral blood and the aorta.
Clin Exp Immunol
; 217(2): 183-194, 2024 Jul 12.
Article
en En
| MEDLINE
| ID: mdl-38766690
ABSTRACT
Takayasu arteritis (TAK) is a granulomatous vasculitis that affects large arteries. T cells are important in TAK pathophysiology as these cells orchestrate granulomatous infiltration in arteries. This study aims to evaluate effector CD4+ T cells in the peripheral blood and the aortic wall of TAK patients and to analyze associations with disease activity and therapy. We performed a longitudinal study including 30 TAK patients and 30 controls. CD3+ T cells, CD3+CD4- T cells, CD4+ T cells, and Th1, Th2, and Th17 cells were evaluated in peripheral blood by flow cytometry, and the expression of CD4, CD8, Tbet, GATA-3, and RORγT was analyzed in the aorta of six patients by immunohistochemistry. TAK patients presented lower CD3+ T cells and CD4+ T cells (Pâ
=â
0.031 and Pâ
=â
0.039, respectively) than controls. Patients with active disease and those in remission had higher proportions of Th17 cells than controls (Pâ
=â
0.016 and Pâ
=â
0.004, respectively). Therapy for TAK did not result in significant differences concerning CD4+ effector T-cell subpopulations. Disease duration correlated with the number and percentage of Th2 cells (rhoâ
=â
-0.610 and rhoâ
=â
-0.463, respectively) and with Th17 cells (rhoâ
=â
-0.365 and rhoâ
=â
-0.568). In the aorta, the expression of CD8 was higher than CD4, whereas GATA-3, Tbet, and RORγT were expressed in this order of frequency. In conclusion, TAK patients present an increased Th17 response in the peripheral blood regardless of disease activity, whereas in the aortic tissue CD8 cells and the Th2 response were predominant.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Aorta
/
Linfocitos T CD4-Positivos
/
Subgrupos de Linfocitos T
/
Arteritis de Takayasu
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Exp Immunol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Brasil